{"transactions":[{"id":723867,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"Middleton Fred A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T12:45:12.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":248972,"price":0.8033,"value":199999.2076,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP (\"SVP VI Co-Investment, LP\", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the \"Sanderling VI Securities\"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1063272,"source":{"system":"sec-edgar","filing":"0001267959-26-000003","document":"form4-06292026_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000126795926000003/form4-06292026_080608.xml","form_type":"4"}},{"id":1100961,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T22:18:33.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders."}],"balance_after":10000,"derivative":{"exercise_price":1.65,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-018297","document":"form4-06262025_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588925018297/form4-06262025_100629.xml","form_type":"4"}},{"id":1100960,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T22:18:33.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":19687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of CalciMedica, Inc. (the \"Company\") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the \"Amended 2023 EIP\") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025."}],"balance_after":19687,"derivative":{"exercise_price":1.53,"expiration_date":"2035-04-22","underlying":"Common Stock","underlying_shares":19687},"source":{"system":"sec-edgar","filing":"0001415889-25-018297","document":"form4-06262025_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588925018297/form4-06262025_100629.xml","form_type":"4"}},{"id":1100959,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T22:18:33.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":6562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of CalciMedica, Inc. (the \"Company\") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the \"Amended 2023 EIP\") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":6562,"derivative":{"exercise_price":1.53,"expiration_date":"2035-04-22","underlying":"Common Stock","underlying_shares":6562},"source":{"system":"sec-edgar","filing":"0001415889-25-018297","document":"form4-06262025_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588925018297/form4-06262025_100629.xml","form_type":"4"}},{"id":1100958,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T22:18:33.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of CalciMedica, Inc. (the \"Company\") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the \"Amended 2023 EIP\") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025."}],"balance_after":10000,"derivative":{"exercise_price":1.53,"expiration_date":"2035-04-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-018297","document":"form4-06262025_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588925018297/form4-06262025_100629.xml","form_type":"4"}},{"id":1168663,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":0.89,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168662,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.39,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168661,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168660,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168659,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.85,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168658,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168657,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.82,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168656,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each option to purchase Shares (each, an \"Option\")  that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an \"In the Money Option\"), to the extent unvested, was accelerated and became fully vested and exercisable.  Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.25,"expiration_date":"2028-03-27","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168655,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":207523,"price":8.55,"value":1774321.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 4, 2025, by and among Chimerix, Inc. (\"Chimerix\"),  Jazz Pharmaceuticals Public Limited Company (\"Parent\") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the \"Offer\") for all outstanding shares of common stock of Chimerix (each, a \"Share\") for an offer price of $8.55 per Share in cash (the \"Offer Price\"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the \"Effective Time\"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168654,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":531861,"price":8.55,"value":4547411.55,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 4, 2025, by and among Chimerix, Inc. (\"Chimerix\"),  Jazz Pharmaceuticals Public Limited Company (\"Parent\") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the \"Offer\") for all outstanding shares of common stock of Chimerix (each, a \"Share\") for an offer price of $8.55 per Share in cash (the \"Offer Price\"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the \"Effective Time\"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168653,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2776093,"price":8.55,"value":23735595.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 4, 2025, by and among Chimerix, Inc. (\"Chimerix\"),  Jazz Pharmaceuticals Public Limited Company (\"Parent\") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the \"Offer\") for all outstanding shares of common stock of Chimerix (each, a \"Share\") for an offer price of $8.55 per Share in cash (the \"Offer Price\"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the \"Effective Time\"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168652,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"price":8.55,"value":513000.0,"ownership":{"direct":false,"nature":"Middleton Childrens 2015 Irrevocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 4, 2025, by and among Chimerix, Inc. (\"Chimerix\"),  Jazz Pharmaceuticals Public Limited Company (\"Parent\") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the \"Offer\") for all outstanding shares of common stock of Chimerix (each, a \"Share\") for an offer price of $8.55 per Share in cash (the \"Offer Price\"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the \"Effective Time\"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1168651,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T16:14:24.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"price":8.55,"value":342000.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 4, 2025, by and among Chimerix, Inc. (\"Chimerix\"),  Jazz Pharmaceuticals Public Limited Company (\"Parent\") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the \"Offer\") for all outstanding shares of common stock of Chimerix (each, a \"Share\") for an offer price of $8.55 per Share in cash (the \"Offer Price\"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the \"Effective Time\"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-011076","document":"form4-04212025_080421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588925011076/form4-04212025_080421.xml","form_type":"4"}},{"id":1340261,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-07T00:12:27.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":4800,"price":2.65,"value":12720.0,"ownership":{"direct":true},"balance_after":36514,"source":{"system":"sec-edgar","filing":"0001415889-24-028563","document":"form4-12072024_121223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924028563/form4-12072024_121223.xml","form_type":"4"}},{"id":1375183,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T20:04:53.000Z","date":"2024-11-01","kind":"purchase","planned":false,"acquired":true,"shares":877,"price":3.75,"value":3288.75,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":22479,"source":{"system":"sec-edgar","filing":"0001415889-24-026102","document":"form4-11052024_081149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924026102/form4-11052024_081149.xml","form_type":"4"}},{"id":1375182,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T20:04:53.000Z","date":"2024-11-01","kind":"purchase","planned":false,"acquired":true,"shares":86867,"price":3.75,"value":325751.25,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP  (\"SVP VI Co-Investment, LP\", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the \"Sanderling VI Securities\"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":814300,"source":{"system":"sec-edgar","filing":"0001415889-24-026102","document":"form4-11052024_081149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924026102/form4-11052024_081149.xml","form_type":"4"}},{"id":1375181,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T20:04:53.000Z","date":"2024-11-01","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":3.75,"value":75000.0,"ownership":{"direct":true},"balance_after":31714,"source":{"system":"sec-edgar","filing":"0001415889-24-026102","document":"form4-11052024_081149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924026102/form4-11052024_081149.xml","form_type":"4"}},{"id":1379551,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-30T20:00:11.000Z","date":"2024-10-28","kind":"gift","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"On October 28, 2024, the Reporting Person transferred 60,000 shares of the Company's common stock to Middleton Childrens 2015 Irrevocable Trust for no consideration.  The Reporting Person is trustee of the trust and members of his immediate family are beneficiaries of the trust.  The Reporting Person remains the beneficial owner of the securities held by the trust."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001415889-24-025802","document":"form4-10302024_081003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588924025802/form4-10302024_081003.xml","form_type":"4"}},{"id":1420704,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-08-28T23:12:44.000Z","date":"2024-08-27","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024."}],"balance_after":10000,"derivative":{"exercise_price":4.16,"expiration_date":"2034-08-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-022506","document":"form4-08282024_110840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924022506/form4-08282024_110840.xml","form_type":"4"}},{"id":1472361,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T11:14:58.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting."}],"balance_after":60000,"derivative":{"exercise_price":0.89,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-017772","document":"form4-06212024_030654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000141588924017772/form4-06212024_030654.xml","form_type":"4"}},{"id":1537522,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-04-23T01:46:08.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":4.16,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-011351","document":"form4-04232024_010401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924011351/form4-04232024_010401.xml","form_type":"4"}},{"id":1670823,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":14372,"price":0.125,"value":1796.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14372,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":14372},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670822,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":14372,"price":0.125,"value":1796.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14372,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":14372},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670821,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":1960,"price":0.125,"value":245.0,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":1960,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":1960},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670820,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":1960,"price":0.125,"value":245.0,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":1960,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":1960},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670819,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":6592,"price":0.125,"value":824.0,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":6592,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":6592},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670818,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":6592,"price":0.125,"value":824.0,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":6592,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":6592},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670817,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":25516,"price":0.125,"value":3189.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":25516,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":25516},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670816,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":25516,"price":0.125,"value":3189.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":25516,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":25516},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670815,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":97236,"price":0.125,"value":12154.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":97236,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":97236},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670814,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":97236,"price":0.125,"value":12154.5,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":97236,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":97236},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670813,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":72338,"price":0.125,"value":9042.25,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":72338,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":72338},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670812,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":72338,"price":0.125,"value":9042.25,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":72338,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":72338},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670811,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":121678,"price":0.125,"value":15209.75,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":121678,"derivative":{"exercise_price":7.15,"exercise_date":"2024-01-23","expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":121678},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670810,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":121678,"price":0.125,"value":15209.75,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":121678,"derivative":{"exercise_price":5.36,"exercise_date":"2024-01-23","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":121678},"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670809,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":28744,"price":3.702,"value":106410.288,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":30292,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670808,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":3920,"price":3.702,"value":14511.84,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":21602,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670807,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":13184,"price":3.702,"value":48807.168,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP (\"SVP VII, LP\", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the \"Sanderling VII Shares\"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":27609,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670806,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":51032,"price":3.702,"value":188920.464,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":114260,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670805,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":194472,"price":3.702,"value":719935.344,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP (\"SVP VII, LP\", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the \"Sanderling VII Shares\"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":435148,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670804,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":144676,"price":3.702,"value":535590.552,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":727433,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1670803,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-26T01:00:34.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":243356,"price":3.702,"value":900903.912,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP (\"SVP VI, LP\", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the \"Sanderling VI Shares\"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":946744,"source":{"system":"sec-edgar","filing":"0001415889-24-001831","document":"form4-01252024_080106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000141588924001831/form4-01252024_080106.xml","form_type":"4"}},{"id":1734960,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T15:28:44.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":17295,"price":0.9553,"value":16521.9135,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9500 to $0.9600, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001209191-23-056008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123056008/doc4.xml","form_type":"4"}},{"id":1744422,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T16:39:41.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":2705,"price":0.92,"value":2488.6,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"balance_after":82705,"source":{"system":"sec-edgar","filing":"0001209191-23-055026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123055026/doc4.xml","form_type":"4"}},{"id":1773449,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T15:58:48.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9818,"value":19636.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.9746 to $0.985, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001209191-23-050548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123050548/doc4.xml","form_type":"4"}},{"id":1842608,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-28T23:51:33.000Z","date":"2023-05-08","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":3.25,"expiration_date":"2033-05-07","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-040097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123040097/doc4.xml","form_type":"4"}},{"id":1859283,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T16:30:27.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting."}],"balance_after":60000,"derivative":{"exercise_price":1.39,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-23-036329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123036329/doc4.xml","form_type":"4"}},{"id":1860340,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-10T01:19:32.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":714,"price":5.2,"value":3712.8,"ownership":{"direct":true},"balance_after":11714,"source":{"system":"sec-edgar","filing":"0001209191-23-036129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123036129/doc4.xml","form_type":"4"}},{"id":1862045,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:12:06.000Z","date":"2023-06-07","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":5.2,"value":2600.0,"ownership":{"direct":true},"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-23-035613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123035613/doc4.xml","form_type":"4"}},{"id":1862044,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:12:06.000Z","date":"2023-06-06","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":4.8808,"value":2440.4,"ownership":{"direct":true},"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001209191-23-035613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123035613/doc4.xml","form_type":"4"}},{"id":1882386,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-22T19:23:23.000Z","date":"2023-05-19","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.85,"value":28500.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-23-031382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123031382/doc4.xml","form_type":"4"}},{"id":1935991,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-29T12:41:51.000Z","date":"2023-03-28","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.2076,"value":24152.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.2000 to $1.2100, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-23-021480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123021480/doc4.xml","form_type":"4"}},{"id":1941488,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":167,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F33","text":"Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":167,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":167},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941487,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":113,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F32","text":"Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":113,"derivative":{"exercise_price":27.94,"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":113},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941486,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":840,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F31","text":"Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":840,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":840},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941485,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":569,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F30","text":"Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":569,"derivative":{"exercise_price":27.94,"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":569},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941484,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":3249,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F29","text":"Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":3249,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":3249},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941483,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":2203,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F28","text":"Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":2203,"derivative":{"exercise_price":27.94,"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":2203},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941482,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":12380,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F27","text":"Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":12380,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":12380},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941481,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":8393,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F26","text":"Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":8393,"derivative":{"exercise_price":27.94,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":8393},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941480,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":183,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F25","text":"Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":183,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":183},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941479,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":237,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F24","text":"Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":237,"derivative":{"exercise_price":27.94,"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":237},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941478,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":15403,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F23","text":"Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":15403,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":15403},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941477,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":6852,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F22","text":"Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":6852,"derivative":{"exercise_price":27.94,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":6852},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941476,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":1910,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":1910,"derivative":{"exercise_price":26.74,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":1910},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941475,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":2685,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":2685,"derivative":{"exercise_price":27.94,"expiration_date":"2026-06-25","underlying":"Common Stock","underlying_shares":2685},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941474,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":16539,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Received in exchange for a warrant to purchase 574,296 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":16539,"derivative":{"exercise_price":27.94,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":16539},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941473,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":2672,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":2672,"derivative":{"exercise_price":26.74,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":2672},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941472,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":5760,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Immediately exercisable."}],"balance_after":5760,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-24","underlying":"Common Stock","underlying_shares":5760},"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941471,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":8176,"ownership":{"direct":false,"nature":"By Golden Triangle Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Received in exchange for 283,866 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":8176,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941470,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":1548,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":1548,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941469,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":47052,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII (Canada), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Received in exchange for 1,633,699 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":47052,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941468,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":14425,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII Annex Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14425,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941467,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":256852,"ownership":{"direct":false,"nature":"By Sanderling Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in exchange for 8,918,437 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP (\"SVP VII, LP\", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the \"Sanderling VII Shares\"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":256852,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941466,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":8884,"ownership":{"direct":false,"nature":"By Sanderling VI Limited Partnership"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":8884,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941465,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":7456,"ownership":{"direct":false,"nature":"By Sanderling VI Beteligungs GmbH & Co KG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":7456,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941464,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":17682,"ownership":{"direct":false,"nature":"By Sanderling Ventures Management VI"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":17682,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941463,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":582757,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI Co-Investment Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":582757,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":1941462,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-23T00:54:44.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":703388,"ownership":{"direct":false,"nature":"By Sanderling Venture Partners VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. (\"CalciMedica\") pursuant to an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the \"Merger\"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP (\"SVP VI, LP\", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the \"Sanderling VI Shares\"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":703388,"source":{"system":"sec-edgar","filing":"0001209191-23-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000120919123020684/doc4.xml","form_type":"4"}},{"id":2147744,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T12:21:23.000Z","date":"2022-09-29","kind":"purchase","acquired":true,"shares":20000,"price":1.8588,"value":37176.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-22-051733","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919122051733/doc4.xml","form_type":"4"}},{"id":2222266,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T11:12:00.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2023 annual stockholder meeting."}],"balance_after":50000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-039119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919122039119/doc4.xml","form_type":"4"}},{"id":2262291,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-20T15:29:06.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":20000,"price":2.0369,"value":40738.0,"ownership":{"direct":false,"nature":"Fred A. Middleton Separate Property Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.02 to $2.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-22-030943","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919122030943/doc4.xml","form_type":"4"}},{"id":2652241,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T17:37:18.000Z","date":"2021-06-28","kind":"purchase","acquired":true,"shares":6950,"price":7.83,"value":54418.5,"ownership":{"direct":true},"balance_after":207523,"source":{"system":"sec-edgar","filing":"0001209191-21-043709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919121043709/doc4.xml","form_type":"4"}},{"id":2652240,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T17:37:18.000Z","date":"2021-06-25","kind":"purchase","acquired":true,"shares":3050,"price":7.78,"value":23729.0,"ownership":{"direct":true},"balance_after":200573,"source":{"system":"sec-edgar","filing":"0001209191-21-043709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919121043709/doc4.xml","form_type":"4"}},{"id":2655071,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T17:28:11.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2022 annual stockholder meeting."}],"balance_after":35000,"derivative":{"exercise_price":7.84,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-21-043352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919121043352/doc4.xml","form_type":"4"}},{"id":3110822,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T12:40:24.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting."}],"balance_after":35000,"derivative":{"exercise_price":2.85,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-036523","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919120036523/doc4.xml","form_type":"4"}},{"id":3209269,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T12:19:02.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":50000,"price":1.398,"value":69900.0,"ownership":{"direct":true},"balance_after":197523,"source":{"system":"sec-edgar","filing":"0001209191-20-019132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919120019132/doc4.xml","form_type":"4"}},{"id":3373135,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-13T16:14:54.000Z","date":"2019-11-13","kind":"purchase","acquired":true,"shares":30000,"price":1.8189,"value":54567.0,"ownership":{"direct":true},"balance_after":147523,"source":{"system":"sec-edgar","filing":"0001209191-19-056337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119056337/doc4.xml","form_type":"4"}},{"id":3373134,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-13T16:14:54.000Z","date":"2019-11-11","kind":"purchase","acquired":true,"shares":20000,"price":1.6595,"value":33190.0,"ownership":{"direct":true},"balance_after":117523,"source":{"system":"sec-edgar","filing":"0001209191-19-056337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119056337/doc4.xml","form_type":"4"}},{"id":3480333,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T14:32:33.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting."}],"balance_after":21000,"derivative":{"exercise_price":3.37,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-19-038721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119038721/doc4.xml","form_type":"4"}},{"id":3530168,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T17:21:45.000Z","date":"2019-05-10","kind":"purchase","acquired":true,"shares":30000,"price":2.9226,"value":87678.0,"ownership":{"direct":true},"balance_after":97523,"source":{"system":"sec-edgar","filing":"0001209191-19-029414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119029414/doc4.xml","form_type":"4"}},{"id":3721097,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T17:54:50.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":19500,"price":13.19,"value":257205.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":10.81,"expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001104659-18-074362","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000110465918074362/a4.xml","form_type":"4"}},{"id":3721096,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T17:54:50.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":19500,"price":21.73,"value":423735.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2027-05-04","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001104659-18-074362","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000110465918074362/a4.xml","form_type":"4"}},{"id":3721095,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T17:54:50.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":13500,"price":20.65,"value":278775.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2026-05-05","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-18-074362","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000110465918074362/a4.xml","form_type":"4"}},{"id":3721094,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":34786,"kind":"person","name":"Middleton Fred A","position":1,"cik":"0001267959","reported_name":"MIDDLETON FRED A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T17:54:50.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":13500,"price":17.98,"value":242730.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":6.02,"expiration_date":"2025-05-14","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-18-074362","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1267959/000110465918074362/a4.xml","form_type":"4"}}],"next_cursor":"2018-12-21T17:54:50.000000Z,3721094"}